Biophytis S.A. (BPTS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.0750 |
| Open | 1.0000 |
| Bid | 0.4040 x 1000 |
| Ask | 1.1000 x 800 |
| Day's Range | 0.9296 - 1.1300 |
| 52 Week Range | 0.9296 - 10.6900 |
| Volume | |
| Avg. Volume | 10,998 |
| Market Cap | 14.062M |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.9600 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.00 |
- ACCESSWIRE
Biophytis Announces the Drawing of the Second Tranche of Ornane Under the 2021 Atlas Contract for €4 Million
On June 14, 2021, Biophytis announced a convertible line of €32 million from Atlas. The financing instrument allows the issuance of 1,280 ORNANE, at a par value of €25,000 each.
- ACCESSWIRE
Biophytis Presents the Development of Sarconeos (BIO101) in Phase 3 for the Treatment of Sarcopenia at the 15th SCWD International Congress
This oral presentation given by Drs. Waly Dioh and Cendrine Tourette and entitled: "BIO101 in development for the treatment of Sarcopenia" summarises the major milestones in the development of Sarconeos (BIO101) that have already been achieved, mainly the results of the SARA-INT Phase 2 study as well as the outline of SARA Phase 3 study that the Company intends to initiate before the end of 2022.
- ACCESSWIRE
Biophytis: Results of the Combined General Meeting on June 21, 2022
Thanks to the mobilization of shareholders, the CGM could be held on second call with a quorum of more than 23% of the shareholders present or represented. The results of the votes of the combined General Meeting will be available on Biophytis' website from June 23, 2022, under the section - Investors - General Assembly.
